Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Neither Norway nor Singapore: Decoding Canada’s new sovereign wealth fund

May 1, 2026

Bevacizumab Biosimilars Market Trastuzumab Biosimilars Market Analysis Report 2026: $2.42 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

May 1, 2026

B2BROKER Group Puts AI at the Core of B2TRADER as Technology Enters a New Era

May 1, 2026

Adalimumab, Infliximab and Etanercept Biosimilars Trastuzumab Biosimilars Research Report 2026: $8.05 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2035

May 1, 2026

Birdfy’s smart bird feeder is down to its best-ever price for Mother’s Day

May 1, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Confluent Medical Technologies Names Tom Testa as Chief Operating Officer
Press Release

Confluent Medical Technologies Names Tom Testa as Chief Operating Officer

By News RoomMay 1, 20263 Mins Read
Confluent Medical Technologies Names Tom Testa as Chief Operating Officer
Share
Facebook Twitter LinkedIn Pinterest Email

SCOTTSDALE, Ariz., May 01, 2026 (GLOBE NEWSWIRE) — Confluent Medical Technologies, Inc. (“Confluent”), a leading medical device and materials science contract manufacturer specializing in Nitinol and polymer components, today announced that Tom Testa, has been appointed as Chief Operating Officer (“COO”) for the company, effective April 29th, 2026.

“We are thrilled to welcome Tom to Confluent,” said Dean Schauer, Confluent’s President, CEO, and Chairman. “Tom has exceptional experience in all aspects of Executive Leadership in the Medical Device Manufacturing and Development space as well as leadership across multiple, successful, MedTech organizations. As Confluent continues its significant growth, the addition of Tom to our company will further enhance the strength of our industry-leading team.”

As COO, Mr. Testa’s responsibilities will span global operations, and he will oversee Confluent’s operations, supply chain, global product development, and environmental health & safety.

Mr. Testa joins Confluent from Corza Medical where he served as CEO and CFO. Prio to that, Tom served as Vice President & General Manager of the Nordson Medical business which he joined following the acquisition of the Vention Medical Advanced Technologies Business where he served as President. Tom holds a Bachelor of Science degree in Chemical Engineering from New Jersey Institute of Technology as well as an MBA in Finance from New York University.

Commenting on his appointment, Mr. Testa said: “I’m excited to join Confluent at such a pivotal moment in its growth. The company has built a strong reputation as a trusted partner to leading medical device innovators, grounded in its differentiated materials science expertise and vertically integrated manufacturing capabilities. I look forward to working with this talented team to further strengthen operational excellence, expand our global footprint, and help drive the next phase of sustainable growth for our customers and the patients they serve.”

About Confluent Medical Technologies, Inc.:
Confluent Applies Materials Science to MedTech Innovation. Confluent specializes in the expert design, development, and large-scale manufacturing of interventional catheter-based devices and implants. Customers rely on Confluent’s expertise in Nitinol material and components, balloon and complex catheters, high-precision polymer tubing, and implantable textiles. With facilities in Fremont and Orange County, California; Warwick, Rhode Island; Windham, Maine; Austin, Texas; Chattanooga, Tennessee; San Jose, Costa Rica; and Hyderabad, India, Confluent has earned the confidence of the leaders in the medical device community through a proven track record of innovative materials science, engineering, and manufacturing. For more information, visit confluentmedical.com.

Media:
Brittany Mai- [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e39458f8-b884-4738-b1f0-5dd6046a9d4e

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Bevacizumab Biosimilars Market Trastuzumab Biosimilars Market Analysis Report 2026: $2.42 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

B2BROKER Group Puts AI at the Core of B2TRADER as Technology Enters a New Era

Adalimumab, Infliximab and Etanercept Biosimilars Trastuzumab Biosimilars Research Report 2026: $8.05 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2035

Whitespace Makes Iris, AI Intelligence Analysis Agent, Generally Available to Authorized DoW and IC Users

Based Eggman Announces Stage 3 Presale Progress

Systemic Mastocytosis (SM) Treatment Market 2026-2035: Industry to More Than Double in Size, Led by Sanofi, AdvaCare Pharma, and Cogent Biosciences

Investment Banking and Trading Services Market Analysis Report 2026: Bulge-Bracket Banks vs. Elite Boutiques

Shares, Opportunities and Strategies in the $1.7 Billion Ice Cream Maker Market, 2026-2035

Experts Highlight What Parents Need to Know About Child and Adolescent Mental Health

Editors Picks

Bevacizumab Biosimilars Market Trastuzumab Biosimilars Market Analysis Report 2026: $2.42 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

May 1, 2026

B2BROKER Group Puts AI at the Core of B2TRADER as Technology Enters a New Era

May 1, 2026

Adalimumab, Infliximab and Etanercept Biosimilars Trastuzumab Biosimilars Research Report 2026: $8.05 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2035

May 1, 2026

Birdfy’s smart bird feeder is down to its best-ever price for Mother’s Day

May 1, 2026

Latest News

Whitespace Makes Iris, AI Intelligence Analysis Agent, Generally Available to Authorized DoW and IC Users

May 1, 2026

Based Eggman Announces Stage 3 Presale Progress

May 1, 2026

Systemic Mastocytosis (SM) Treatment Market 2026-2035: Industry to More Than Double in Size, Led by Sanofi, AdvaCare Pharma, and Cogent Biosciences

May 1, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version